News List

Hetero launches AbbVie’s Humira biosimilar Adalimumab


Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF), indicated for the treatment of rheumatoid arthritis and other auto-immune disorders

By Team ABLE

Hyderabad-based generic pharmaceutical company, Hetero Labs Ltd has announced on Jan 3, 2018 that it has launched its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘Mabura’ in India. Hetero Healthcare will market and distribute the product in the country, according to a release.

The release further said that Hetero will manufacture the product at its dedicated manufacturing facility for Biologics, based at Hyderabad.
Mabura will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously. Hetero’s Mabura is the Biosimilar version of AbbVie’s Humira. Adalimumab is the first fully human monoclonal antibody which was first approved by US FDA in 2002.

Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF), indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, etc.